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Abstract	
	
Background:	 Preclinical	 research	 involving	 non-human	 animals	 has	 made	
important	 contributions	 to	 our	 understanding	 of	 risk-factors	 for	 addiction,	
neuroadaptations	 that	 follow	chronic	drug	exposure,	and	 to	 the	development	of	 some	
efficacious	pharmacotherapies	for	addiction.	Despite	these	contributions,	we	argue	that	
animal	models	of	 addiction	have	 impeded	progress	 in	our	understanding	of	addiction	
and	 its	 treatment	 in	 humans.	Argument:	First	 of	 all,	 the	majority	 of	 pharmacological	
treatments	 that	 were	 initially	 developed	 using	 animal	 models	 have	 failed	 to	 prove	
effective	 for	 the	 treatment	 of	 addiction	 in	 humans,	 resulting	 in	 a	 huge	 waste	 of	
resources.	 Secondly,	 we	 demonstrate	 that	 prevailing	 animal	 models	 that	 portray	
addiction	as	a	disorder	of	compulsion	and	habit	cannot	be	reconciled	with	observations	
that	psychoactive	drug	use	in	humans	is	a	goal-directed	operant	behaviour	that	remains	
under	 the	 control	 of	 its	 consequences,	 even	 in	 people	 who	 are	 addicted.	 Thirdly,	
addiction	may	be	a	uniquely	human	phenomenon	that	is	dependent	on	language,	which	
necessarily	limits	the	validity	of	animal	models.		Finally,	we	argue	that	addicted	brains	
must	 be	 understood	 as	 one	 component	 of	 broader	 networks	 of	 symptoms	 and	
environmental	 and	 social	 factors	 that	 are	 impossible	 to	model	 in	 laboratory	 animals.	
Conclusions:	A	 case	 can	be	made	 that	animal	models	of	 addiction	have	not	 served	us	
well	 in	understanding	and	 treating	addiction	 in	humans.	 It	 is	 important	 to	 reconsider	
some	widely-held	beliefs	about	the	nature	of	addictive	behaviour	in	humans	that	have	
arisen	from	the	zeal	to	translate	observations	of	laboratory	animals.	
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Preclinical	 addiction	 research	 includes	 laboratory	 studies	 with	 rodents	 and	
primates	 that	 characterise	 the	 individual	differences	 that	predispose	 to	addiction	and	
the	neurobiological	adaptations	 that	occur	after	chronic	drug	exposure.	Findings	 from	
these	studies	have	made	important	contributions	to	our	understanding,	including	risk-
factors	 for	 the	 development	 of	 addiction	 (e.g.	 (1)),	 and	 to	 the	 identification	 of	 some	
novel	pharmacotherapies	(2).	Aside	from	these	contributions,	there	is	scepticism	about	
the	contribution	of	animal	models	to	our	understanding	of	addiction	and	its	treatment	
in	humans	(3).	In	this	paper,	we	consider	the	validity	of	animal	models	of	addiction	and	
we	critically	review	the	contribution	of	those	models	to	our	understanding	of	addiction	
in	humans	and	to	the	development	of	effective	treatments.		
	
What	are	‘animal	models	of	addiction’?	
	 Diagnostic	 criteria	 for	 substance	 use	 disorders	 (4)	 include	 physiological	
adaptations	(tolerance	and	withdrawal),	persistence	of	substance	use	despite	negative	
consequences,	 increased	 allocation	 of	 behaviour	 to	 substance	 use	 rather	 than	
competing	rewards,	subjective	craving,	and	continued	substance	use	despite	intentions	
to	cease	or	reduce	it.	Given	the	diversity	of	diagnostic	criteria,	a	unitary	animal	model	of	
addiction	 is	 probably	 unattainable	 (5,	 6).	 This	 is	 important	 in	 the	 broader	 context	 of	
concerns	 about	 the	 predictive	 validity	 of	 animal	 models	 of	 complex	 psychiatric	
disorders,	which	have	prompted	the	pharmaceutical	industry	to	drastically	reduce	their	
funding	of	research	that	relies	on	such	models	to	develop	novel	pharmacotherapies	(7).	
Many	experimental	procedures	such	as	drug	self-administration	and	conditioned	place	
preference	that	were	historically	interpreted	as	animal	models	of	addiction	(8)	are	now	
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understood	 to	be	models	of	 substance	reward,	 instrumentalization,	and	non-addictive	
substance	use,	rather	than	models	of	addiction	(5)(8)(9).	
However	 some	 animal	 models,	 for	 example	 the	 0/3	 criteria	 model	 of	 cocaine	
addiction	(2,	10)	attempt	 to	model	several	of	 the	diagnostic	criteria	 for	substance	use	
disorders	 (4).	This	model	 includes	 laboratory	measures	of	 (i)	persistent	drug-seeking	
when	the	drug	is	signalled	to	be	not	available,	which	is	an	animal	model	of	the	inability	
to	 refrain	 from	 drug-seeking;	 (ii)	 motivation	 to	 obtain	 the	 drug	 under	 a	 progressive	
ratio	reinforcement	schedule,	which	captures	elevated	motivation	for	the	drug,	and	(iii)	
maintenance	of	drug-seeking	and	taking	despite	contingent	punishment	such	as	electric	
shock	(also	known	as	a	‘punishment	schedule’),	which	is	an	animal	model	of	persistent	
drug	 use	 despite	 negative	 consequences.	 This	 and	 similar	 animal	 models	 have	
contributed	to	our	understanding	of	the	neurobiological	changes	that	arise	after	chronic	
drug	 exposure	 and	 that	may	underlie	 the	 development	 of	 apparently	 compulsive	 and	
habitual	drug	seeking	(11,	12).	
	
Animal	models	have	failed	to	deliver	effective	pharmacotherapies	for	addiction	
	 There	 are	 many	 efficacious	 treatments	 for	 addiction	 (13).	 These	 include	
pharmacotherapies	 such	 as	 acamprosate	 and	 naltrexone	 for	 alcohol	 and	 opioid	
dependence	 (14,	 15)	 nicotine	 replacement	 therapy	 and	 varenicline	 for	 smoking	
cessation	 (16),	 and	 psychological	 and	 behavioural	 treatments	 such	 as	 motivational	
interviewing,	cognitive-behavioural	therapy,	and	contingency	management	(17).	When	
considering	the	contribution	of	animal	models,	it	is	important	to	distinguish	predictive	
models	(that	predate	human	clinical	research)	from	postdictive	models,	where	findings	
from	human	clinical	 studies	 are	back-translated	 to	 animal	models	 (18).	 Some	notable	
examples	of	addiction	treatments	that	have	been	studied	in	postdictive	animal	models	
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include	buprenorphine	and	methadone	that	were	initially	developed	as	analgesics	(19),	
nicotine	 replacement	 therapy	 that	 resulted	 from	 observations	 that	 submariners	
switched	 from	 tobacco	 to	 snus	 when	 onboard	 (19),	 and	 some	 psychosocial	
treatments(20)	 that	 are	 adaptations	 of	 treatments	 for	 other	 psychological	 disorders	
(21).	Our	criticism	of	animal	models	focusses	on	predictive	animal	models.		
Efficacious	 pharmacotherapies	 for	 addiction	 that	 can	 be	 at	 least	 partially	
attributed	to	predictive	animal	models	include	acamprosate,	naltrexone,	and	varenicline	
(19).	 For	 example,	 varenicline	 is	 a	 partial	 nicotine	 receptor	 agonist	 that	was	 initially	
tested	in	rodent	models,	where	it	was	shown	to	be	less	reinforcing	than	nicotine	and	led	
to	 reductions	 in	 nicotine	 self-administration	 and	 nicotine-induced	 reinstatement.	 On	
the	basis	of	 these	promising	 findings,	varenicline	was	tested	 in	human	clinical	studies	
where	 it	 was	 shown	 to	 increase	 abstinence	 and	 reduce	 nicotine	 withdrawal	 and	
cravings,	leading	to	its	endorsement	by	NICE	as	a	smoking	cessation	treatment	in	2007	
(22).	 Thus,	 the	 development	 of	 varenicline	 as	 an	 efficacious	 smoking	 cessation	
treatment	can	be	directly	attributed	to	animal	models	of	addiction	(6,	19).	
However,	many	other	medications	were	initially	developed	in	animal	models,	but	
subsequently	 failed	 to	 translate	 to	 clinical	 benefit	 in	 humans	 (see	 (18)	 for	 a	 review).	
Very	few	medications	have	been	approved	for	the	treatment	of	addiction	in	the	past	20	
years	and	those	that	have	are	only	slightly	better	than	older	drugs	(3,	23).	For	example,	
despite	promising	findings	in	animal	models,	the	recently	developed	opioid	antagonist	
nalmefene	has	trivial	advantages	over	the	older	(and	considerably	cheaper)	medication	
naltrexone	for	the	treatment	of	alcohol	use	disorders	in	humans	(24).	Another	example	
is	 memory	 reconsolidation	 interventions,	 which	 were	 advanced	 based	 on	
demonstrations	 that	 disruption	 of	 drug-related	 memories	 led	 to	 reductions	 in	 drug-
seeking	 behaviour	 in	 rodents	 (5).	 However,	 trials	 of	 pharmacotherapies	 that	 disrupt	
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memory	 reconsolidation	 have	 not	 revealed	 clinical	 benefit	 in	 humans	 with	 addiction	
(25,	26).		Similarly,	D-cycloserine,	a	pharmacological	agent	that	facilitates	extinction	of	
cue	 reactivity	 in	 animal	 models,	 does	 not	 confer	 clinical	 benefit	 in	 humans	 (27).	
Aripiprazole,	 another	 candidate	 pharmacotherapy	 for	 the	 treatment	 of	 cocaine	
dependence,	 reduced	 cocaine	 self-administration	 in	 animal	models,	 but	performed	no	
better	than	placebo	(28)	or	led	to	increased	cocaine	use	(29,	30),	in	trials	with	humans.		
Translational	 failures	 such	 as	 these	might	 be	 brushed	 aside	with	 reference	 to	
methodological	 issues	 in	clinical	 trials,	 such	as	high	placebo	response	rates	 that	mask	
the	effectiveness	of	a	candidate	treatment,	poor	participant	engagement,	or	lower	drug	
dosage	in	clinical	trials	than	in	animal	research	in	order	to	minimize	side	effects	(2).	Our	
view	 is	 that	 these	 failures	 illustrate	 the	 inability	 of	 animal	 models	 to	 capture	 the	
complex	nature	of	addiction	and	its	treatment,	and	the	complexity	of	conducting	clinical	
trials	with	 humans.	 A	 further	 objection	 is	 that,	 until	 fairly	 recently,	 animal	 studies	 of	
medication	development	used	models	of	non-addictive	drug	use	rather	than	models	of	
addiction,	which	may	explain	why	a	 candidate	medication	 that	had	a	 robust	 effect	on	
non-addictive	 drug	 use	 in	 laboratory	 animals	 failed	 to	 translate	 to	 clinical	 benefit	 for	
humans	 with	 addiction	 (9).	 The	 validity	 of	 this	 viewpoint	 depends	 on	 the	 extent	 to	
which	a	valid	animal	model	of	addiction	is	attainable,	a	point	to	which	we	return	later.					
	
Findings	from	animal	models	of	addiction	have	generated	a	misleading	
picture	of	the	nature	of	addictive	behaviour	in	humans	
	 Next,	 we	 consider	 the	 influence	 of	 animal	 models	 on	 conceptualisations	 of	
addiction	 that	 are	 widely	 accepted	 and	 largely	 unchallenged	 in	 the	 scientific	 and	
medical	 literature,	 and	 increasingly	 accepted	 by	 non-specialists.	 For	 example,	 Everitt	
and	colleagues	(12)	reviewed	the	“burgeoning,	supportive	evidence”	for	the	notion	that	
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“drug	addiction	can	be	viewed	as	a	transition	from	voluntary,	recreational	drug	use	to	
compulsive	 drug-seeking	 habits”	 (p23).	 Other	 influential	 theorists	 such	 as	 Wise	 and	
Koob	 (11)	 and	 Volkow,	 Koob	 &	 McLellan	 (31)	 also	 claim	 that	 addiction	 involves	 a	
transition	 to	 compulsive	 and	 habitual	 behaviour,	 although	 their	 explanations	 for	 the	
neurobiological	adaptations	that	underlie	these	behavioral	changes	differ.		
Compulsive	 behaviour,	 defined	 as	 “the	 maladaptive	 persistence	 of	 responding	
despite	 adverse	 consequences”	 (12)	 is	 modelled	 in	 animals	 by	 measuring	 the	
persistence	of	instrumental	responding	for	drug	despite	contingent	punishment	such	as	
electric	 shock,	 which	 is	 a	 component	 of	 the	 0	 /	 3	 criteria	 model	 (2,	 10).	 Habitual	
behaviour,	 defined	 as	 instrumental	 behaviour	 that	 is	 independent	 of	 the	 value	 of	 its	
outcome	(12),	can	be	inferred	if	animals	persist	with	instrumental	responding	for	drug	
despite	 devaluation	 of	 the	 drug	 outcome.	 The	 aforementioned,	 highly	 influential	
depictions	of	addiction	as	a	disorder	of	compulsive	and	habitual	behaviour	are	largely	
underpinned	by	evidence	obtained	from	these	animal	procedures	(5,	12).	
	 	For	 present	 purposes,	 the	 critical	 question	 is:	 to	 what	 the	 extent	 can	 human	
drug-seeking	 behaviour	 be	 characterised	 as	 compulsive	 or	 habitual?	 Heather	 (32)	
summarizes	 several	 observations	 that	 clearly	 contradict	 this	 characterization.	 For	
example,	drug	use	is	an	operant	behaviour	that	remains	sensitive	to	 its	consequences,	
as	 evidenced	 by	 the	 effectiveness	 of	 contingency	 management	 for	 the	 treatment	 of	
addiction	(33).	That	is,	people	with	addiction	are	able	to	refrain	from	using	drugs	if	they	
receive	monetary	rewards	(or	other	incentives)	for	doing	so.	Therefore,	drug	use	is	not	
‘compulsive’	at	the	time	it	is	carried	out	(32).	Furthermore,	people	with	addiction	report	
high	 levels	 of	 problem	 solving	 in	 order	 to	 obtain	 drugs	 (34),	 rather	 than	 being	 the	
inflexible	 automatons	 that	 are	 portrayed	 in	 some	 of	 the	 aforementioned	 theoretical	
accounts.	Demonstrations	of	habitual	and	compulsive	drug-seeking	that	is	insensitive	to	
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its	 consequences	 in	 animals	 after	 chronic	 drug	 exposure	 cannot	 be	 consistently	
replicated	in	human	addicts,	in	whom	goal-directed	control	over	behaviour	appears	to	
be	intact	(35).	A	broader	problem	for	any	theoretical	account	that	depicts	addiction	as	a	
compulsive	 disorder	 in	which	 control	 over	 drug	 use	 has	 been	 lost	 is	 the	 observation	
that	 most	 people	 with	 addiction	 eventually	 recover,	 often	 in	 the	 absence	 of	 any	
treatment	(36).		
Until	recently,	animal	models	failed	to	consider	a	number	of	factors	that	have	a	
pronounced	 effect	 on	 drug-seeking	 behaviour.	 As	 summarized	 by	 Ahmed	 (37):	 “In	
standard	self-administration	settings,	animals	have	no	choice	than	drug	use.	As	a	result,	
serious	 doubt	 exists	 about	 the	 interpretation	 of	 drug	 use	 in	 laboratory	 animals.	 Is	 it	
symptomatic	of	an	underlying	addiction	state	or	merely	an	expectable	response	to	lack	
of	 choice”?	 The	 landmark	 ‘Rat	 Park’	 studies	 (38)	 were	 the	 first	 to	 demonstrate	 that	
morphine-exposed	rats	preferred	plain	water	over	morphine	water	if	they	were	tested	
in	an	enriched	social	environment	compared	to	if	they	were	tested	alone	in	their	home	
cage.	 Although	 there	 are	methodological	 weaknesses	 with	 the	 Rat	 Park	 studies	 (39),	
Ahmed	and	colleagues	subsequently	conducted	many	rigorously	controlled	studies	that	
demonstrate	that	the	majority	(85-90%)	of	rats	that	rapidly	escalated	their	drug	intake	
when	 given	 free	 access	 to	 it	 would	 switch	 their	 preference	 from	 the	 drug	 to	 an	
alternative	 reinforcer	 such	 as	 saccharin	 if	 given	 the	 choice	between	 the	 two	 (40,	 41).	
Similarly,	 even	 ‘addicted’	 rats	 (based	on	 the	0	/3	crit	model)	prefer	 social	 interaction	
over	the	drug	when	offered	the	choice	between	them	(42).	
These	 findings	 raise	 fundamental	 questions	 about	 the	 extent	 to	 which	 drug	
seeking	in	‘addicted’	rats	is	compulsive	and	habitual,	as	is	commonly	portrayed	(11,	12,	
31),	rather	than	goal-directed	and	sensitive	to	the	presence	of	competing	rewards,	as	it	
is	in	humans.	These	findings	also	have	implications	for	interpretation	of	the	changes	in	
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brain	structure	and	function	that	are	observed	in	laboratory	animals	after	chronic	drug	
exposure,	 and	observations	of	 comparable	 adaptations	 in	humans	with	 addiction	 (12,	
31).	As	noted	by	Ahmed	(37):	“neuroadaptive	changes	documented	in	the	brain	of	these	
rats	 should	 not	 be	 necessarily	 interpreted	 as	 evidence	 for	 addiction-specific	
pathological	changes”	(p179).		
The	 neurobiological	 changes	 that	 characterize	 the	 minority	 (10-15%)	 of	 rats	
who	continue	to	favour	drugs	over	alternative	reinforcers	have	recently	been	studied	in	
animal	 models	 (43);	 these	 findings	 await	 replication.	 Furthermore,	 although	 recent	
animal	 studies	 that	 used	 choice	 tasks	 demonstrated	 that	 chronic	 drug	 use	 leads	 to	
impulsive	and	habitual	responding	and	appears	to	disrupt	goal-directed	behaviour,	this	
appears	 to	 paradoxically	 predispose	 animals	 to	 prefer	 the	 non-drug	 over	 the	 drug	
option	 (41,	44).	This	 is	 a	 challenge	 to	 theoretical	 claims	 that	 chronic	drug	use	 causes	
habitual	and	compulsive	drug-seeking	behaviour	(12).	
Another	 recently	 developed	 animal	 drug	 self-administration	 paradigm	 also	
questions	 the	 importance	 of	 habitual	 and	 inflexible	 behaviour	 in	 the	 development	 of	
addiction.	 Building	 on	 observations	 of	 the	 extent	 of	 planning	 and	 problem	 solving	
reported	by	human	addicts	in	order	to	obtain	drugs	(32),	Singer	et	al.	(45)	developed	a	
novel	cocaine	self-administration	procedure	that	required	rats	to	solve	puzzles	in	order	
to	obtain	access	to	cocaine.	The	rats	were	required	to	solve	different	puzzles	each	time,	
which	 prevented	 drug-seeking	 from	 becoming	 habitual	 and	 inflexible.	 Nonetheless,	
these	 rats	developed	symptoms	of	addiction,	 similar	 to	 those	captured	 in	 the	0/3	crit	
model.	The	implication	is	that	novel	drug	self-administration	procedures	reveal	findings	
that	 are	 fundamentally	 incompatible	 with	 the	 dogma	 that	 addiction	 is	 a	 disorder	 of	
compulsive	and	habitual	drug	self-administration	(11,	12,	31),	but	rather	it	can	involve	
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problem-solving	and	complicated	sequences	of	behaviour,	just	as	it	does	in	humans	(32,	
35).		
It	 is	unfortunate	 that	 the	broader	 scientific	 and	medical	 community	have	been	
misled	 about	 the	 nature	 of	 addiction	 on	 the	 basis	 of	 findings	 from	 studies	 that	 used	
older	animal	models.	On	a	more	optimistic	note,	recent	studies	have	demonstrated	the	
exciting	possibilities	afforded	by	novel	animal	procedures	that	involve	choices	between	
drugs	 versus	 alternative	 reinforcers	 or	 social	 interaction,	 or	 that	 require	 problem	
solving	rather	than	favour	the	development	of	habits.	One	might	argue	that	we	should	
intensify	efforts	 to	develop	and	validate	 these	novel	animal	models,	 and	embrace	any	
rethink	about	the	nature	of	addictive	behaviour	that	is	suggested	by	findings	obtained	
from	 these	 models	 (18,	 40,	 43,	 45).	 However,	 this	 may	 be	 misguided,	 because	 even	
sophisticated	 animal	 models	 cannot	 capture	 features	 of	 addiction	 that	 are	 uniquely	
human,	as	we	discuss	next.			
	
Addiction	may	be	uniquely	human		
	 The	0/3	crit	test	may	be	a	face	valid	model	of	some	of	the	diagnostic	criteria	for	
substance	use	disorders.	However,	at	 least	three	diagnostic	criteria	(4)	are	 impossible	
to	model	in	laboratory	animals	given	their	reliance	on	subjective	states	that	can	only	be	
assessed	with	self-report.	These	are:	(i)	subjective	craving,	(ii)	taking	the	substance	in	
larger	 amounts	 or	 for	 longer	 than	 intended,	 and	 (iii)	 wanting	 to	 cease	 or	 reduce	
substance	 use	 but	 being	 unable	 to.	 Although	diagnostic	manuals	 do	 not	 privilege	 any	
particular	criteria	as	essential	for	diagnosis,	the	latter	criteria	may	be	the	core	features	
of	addiction.	For	example,	Heather	(46)	argues	that	“a	person	is	addicted	to	a	specified	
behaviour	if	they	have	demonstrated	repeated	and	continuing	failures	to	refrain	from	or	
radically	 reduce	 the	behaviour	despite	prior	resolutions	 to	do	 so”	 (p25	emphasis	ours;	
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see	 (47-49)	 for	 similar	 arguments).	 If	 this	 view	 is	 correct,	 this	 raises	 the	 question	 of	
whether	 it	 is	 possible	 to	 capture	 the	 core	 features	 of	 addiction	 in	 animal	 models.	
Punishment	 schedules	 (part	 of	 the	 0	 /3	 crit	 model)	 are	 able	 to	 make	 negative	
consequences	 contingent	 upon	 drug	 self-administration,	 but	 they	 rest	 on	 the	
assumption	that	if	an	animal	persists	with	drug	self-administration	under	a	punishment	
schedule,	 it	 is	doing	 so	despite	making	a	prior	 resolution	 to	do	otherwise.	We	do	not	
anticipate	the	future	development	of	an	animal	model	of	 ‘behaving	in	one	way	despite	
intending	to	act	differently’,	because	such	a	model	would	require	understanding	of	the	
animal’s	subjective	state	(47).		
A	broader	question	is	whether	addiction	can	be	attributed	to	‘the	animal	within	
us’	 or	 the	 ‘human	 within	 us’	 (48).	 Until	 fairly	 recently,	 the	 latter	 view	 was	 widely	
accepted:	 whilst	 nonhuman	 animals	 could	 be	 trained	 to	 self-administer	 drugs,	 they	
could	never	become	‘addicted’	because	of	the	impossibility	of	establishing	if	they	were	
self-administering	drugs	whilst	intending	to	do	otherwise	(50).	More	recently,	addiction	
has	been	attributed	to	‘the	animal	within	us’:	neurobiological	adaptations	in	subcortical	
regions	 that	 are	 shared	 between	 humans	 and	 nonhuman	 animals,	 such	 that	 those	
regions	come	to	dominate	cortical	structures	 that	are	more	developed	 in	humans	and	
other	 primates	 (51).	 However,	 this	 conceptualization	 raises	 another	 problem	 with	
animal	models:	if	addiction	arises,	at	least	in	part,	because	‘human’	brain	structures	are	
somehow	 compromised,	 how	 is	 it	 possible	 to	 model	 addiction	 in	 animals	 that	 have	
qualitatively	different	neurobiology?	(48,	52).	
A	 further	 important	 difference	 between	 animals	 and	 humans	 is	 their	 use	 of	
language,	 which	 plays	 a	 key	 role	 in	 the	 initiation	 of	 drug	 use	 and	 recovery	 from	
addiction.	People	initiate	drug	use	if	they	expect	the	benefits	to	outweigh	the	negative	
consequences	 (53-55).	 These	 expectations	 are	 formed	 from	 peers	 or	 parents	 (56)	 or	
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advertising	 (57),	 before	 any	 direct	 experience	 of	 drug	 use.	 Compare	 this	with	 animal	
models	 of	 addiction,	 where	 initiation	 of	 drug	 self-administration	 is	 either	 accidental	
(from	 the	 animal’s	 point	 of	 view)	 or	 forced	 by	 the	 experimenter	 (40).	 Language	 also	
plays	a	vital	role	in	treatment	and	recovery	from	addiction	in	humans.	For	example,	the	
translational	failure	of	memory	reconsolidation	interventions	for	cocaine	addiction	that	
were	 discussed	 earlier	 (25)	 could	 be	 attributed	 to	 a	 number	 of	 factors	 related	 to	
different	 aspects	 of	 memory	 stabilisation	 and	 reconsolidation.	 However,	 one	
explanation	 for	 this	 translational	 failure	 is	 that	 humans	 understand	 experimental	
procedures	 in	 ways	 that	 animals	 cannot	 (58).	 Specifically,	 studies	 with	 human	
participants	reveal	 that	memory	reconsolidation	mechanisms	are	activated	only	when	
the	 outcome	 of	 an	 event	 is	 uncertain	 (59).	 Therefore,	 memory	 reconsolidation	
interventions	can	only	work	if	participants	reasonably	expect	to	have	an	opportunity	to	
receive	 the	 drug.	 Unlike	 laboratory	 animals,	 participants	 in	 trials	 of	 memory	
reconsolidation	treatments	for	addictions	(e.g.,	25)	have	no	reason	to	believe	they	may	
receive	 the	 drug	 during	 the	 trial;	 therefore	 there	 is	 no	 opportunity	 for	 memory	
reconsolidation	 to	 take	place.	This	between-species	difference	 fundamentally	 changes	
the	context	in	which	memory	reconsolidation	interventions	take	place,	which	may	have	
contributed	 to	 the	 failure	 to	 translate	 findings	 from	 animal	 models	 to	 trials	 with	
humans.		
Additionally,	 ‘talking	 therapies’	 such	 as	 cognitive	 behaviour	 therapy	 and	
motivational	 interviewing,	 and	 self-help	 groups	 such	 as	 Alcoholics’	 Anonymous	 are	
among	the	most	efficacious	treatments	for	addiction	(13,	17,	60).	These	rely	on	verbal	
interactions	 between	 people	 with	 addiction	 and	 therapists	 or	 sponsors	 to	 change	
psychological	constructs	such	as	motivation	to	change	and	coping	skills.	Change	in	these	
psychological	 constructs,	 which	 are	 inferred	 from	 self-report,	 plays	 a	 vital	 role	 in	
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recovery	 from	 addiction.	 For	 example,	 the	 effects	 of	 cognitive-behaviour	 therapy	 on	
alcohol	 abstinence	 among	 drinkers	with	 severe	 alcohol	 dependence	 are	mediated	 by	
improvements	 in	 coping	 skills	 (61).	 Among	 patients	 who	 receive	 motivational	
interviewing	 in	 tandem	 with	 other	 behavioural	 interventions,	 the	 extent	 to	 which	
drinkers	with	alcohol	dependence	verbalize	commitment	to	change	their	drinking	at	the	
start	 of	 treatment	 predicts	 treatment	 success	 (62).	 Changing	 such	 psychological	
constructs	 is	 not	 only	 a	 key	 component	 of	 formal	 therapies,	 but	 also	 underpins	 the	
effectiveness	of	self-help	groups	such	as	Alcoholics	Anonymous	that	support	members	
to	maintain	their	recovery	motivation	and	boost	their	confidence	that	they	are	able	to	
stay	 abstinent	 (60).	 Therefore,	 the	 way	 people	 communicate	 about	 their	 drug	 use	
influences	the	trajectory	of	addiction	from	initiation	to	recovery.	Animal	models	cannot	
model	the	role	of	language	in	addiction,	and	they	will	inevitably	overlook	how	language	
could	impact	the	translation	of	candidate	treatments	from	animal	models	of	addiction	to	
clinical	trials	with	humans.		
	
	
Network	models	expose	the	limited	value	of	animal	models	of	psychiatric	
disorders	
Network	models	of	psychiatric	disorders	attempt	to	model	the	interplay	between	
different	symptoms	of	disorders	(particularly	subjective	states),	and	they	consider	how	
symptom	 networks	 are	 dependent	 on	 the	 broader	 environmental	 context	 (63).	 Such	
models	 “preclude	 the	 identification	 of	 a	 common	 cause	 of	 symptomatology	 with	 a	
neurobiological	 condition”	 (Borsboom	 et	 al.	 (63),	 p1).	 Network	 models	 are	 highly	
relevant	for	addiction	(64,	65).	For	example,	the	diagnostic	criteria	(4)	of	(i)	subjective	
craving	and	(ii)	continued	substance	use	despite	intentions	to	stop	are	unlikely	to	each	
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have	their	own	distinct	neural	substrates;	instead,	the	former	should	contribute	to	the	
latter.	An	example	that	illustrates	the	crucial	role	of	the	broader	context	is	the	current	
opioid	 crisis	 in	 the	 USA,	 which	 can	 be	 attributed	 to	 deindustrialization,	 economic	
decline	and	urban	decay	alongside	massive	increases	in	the	availability	of	prescription	
opioids	 (64).	 These	 examples	 illustrate	 the	 futility	 of	 attempting	 to	map	 addiction	 to	
brain	 function	 independently	 of	 the	 relations	 between	 subjective	 symptoms	 and	 the	
broader	environmental	context.	By	extension,	this	may	account	for	the	poor	predictive	
validity	 and	 explanatory	 power	 of	 animal	 models	 of	 psychiatric	 disorders,	 including	
addiction	(66).	
	 In	 response,	Müller	 (65)	 called	 for	 “constructive	 reductionism”:	 a	 reductionist	
empirical	 approach,	 that	 would	 incorporate	 animal	 models	 for	 testing	 of	 specific	
components	 of	 networks	 including	 the	 biological	 substrates	 of	 specific	 behaviours;	
combined	with	 a	 constructivist	 synthesis	 of	 the	 broader	 network,	 that	 would	 largely	
rely	 on	 observational	 rather	 than	 experimental	 methods	 (e.g.	 (67)).	 We	 agree	 that	
sophisticated	 animal	 models	 that	 incorporate	 social	 factors,	 problem	 solving	 and	 a	
choice	of	reinforcers	should	increase	the	relevance	of	animal	models	of	addiction	to	the	
human	 condition	 (18,	 40,	 45).	 However,	 given	 its	 complex	 nature,	 we	 consider	 it	
unlikely	that	animal	models	will	ever	be	able	to	model	the	relations	between	subjective	
symptoms	and	the	economic	and	social	factors	that	determine	the	onset	and	persistence	
of	addiction	(and	recovery	from	it)	in	humans.		
	
Conclusions	
Animal	models	of	addiction	have	a	poor	 track	 record	 for	 the	 identification	and	
development	 of	 addiction	 treatments	 that	 have	 clinical	 benefit	 in	 humans,	 and	 their	
contribution	has	consistently	been	misrepresented	and	oversold.	More	 fundamentally,	
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animal	models	have	misled	us	about	the	very	nature	of	addiction	in	humans.	One	might	
counter	 that	 recent	 refinements	 in	 animal	 models	 suggest	 reasons	 to	 be	 optimistic	
about	 the	 future,	 in	particular	 that	we	may	soon	discover	 the	molecular	switches	 that	
drive	 persistent	 drug	 preference	 in	 choice	 settings	 (41-43).	 However,	 if	 addiction	 is	
indeed	‘uniquely	human’,	and	largely	dependent	on	language,	causal	inter-relationships	
between	 subjective	 symptoms,	 and	 the	 broader	 social,	 economic	 and	 environmental	
context,	then	such	a	rose-tinted	view	would	be	unwarranted.		
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